Introduction
Mobilization of hematopoietic progenitor cells (HPCs) with G-CSF alone in the hematological steady state offers notable advantages of ease of planning, patient comfort and a reduced number of hospital visits and blood tests. To date, G-CSF at 10 mg/kg/d remains the standard regimen in children, although recent data suggest that increasing and splitting the dosage of G-CSF into twice-daily doses is more efficient. 1 However, this strategy requires more s.c. injections and does not allow the collection of an optimal number of HPCs in a single apheresis for all children. 2 In our experience, 1, 3 an optimal graft (containing at least 5 Â 10 6 CD34 þ cells/kg) was achieved after 4 days of mobilization and with one apheresis (including large volume) in 48/120 patients (40%, 95% confidence interval (CI): 31-49) after mobilization with G-CSF at 10 mg/kg/d for 4 days (four injections) and in 17/32 patients (53%, 95% CI: 36-71) after twice-daily dosage (2 Â 12 mg/kg/d) for 4 days (eight injections). With this last regimen, despite the use of large-volume apheresis, two other teams failed to achieve this optimal value in a single apheresis in more than 50% of children. 2, 4 Thus, finding more efficient welltolerated strategies remains desirable.
Pegfilgrastim is a PEG-conjugated form of r-metHuG-CSF (recombinant methionyl human G-CSF, filgrastim, Amgen, Thousand Oaks, CA, USA) with an increased serum half-life (from 4 up to 33 h) due to decreased renal elimination. Early studies in healthy donors and adult patients showed that pegfilgrastim mobilized HPC efficiently, with the notable advantage of only a single dose administration being necessary instead of multiple s.c. injections. [5] [6] [7] In children, the data on pegfilgrastim are very limited and refer to the prevention and treatment of chemotherapy-induced neutropenia and chemo-induced stem cell mobilization. [8] [9] [10] [11] The objective of this phase IIA study was to evaluate the percentage of children achieving steady-state mobilization of HPCs using pegfilgrastim, that is, an optimal harvest of 5 Â 10 6 CD34 þ cells/kg in one standard apheresis (p3 blood volumes processed (BVP)) after a single injection of 300 mg/kg pegfilgrastim.
Patients and methods

Patients
Children with solid malignancies who were referred to our center for HPC collection for autologous BMT were consecutively invited to enter this phase IIA open-label, single-center prospective study (clinical trials NCT 00695370). Pre-collection treatments and subsequent transplants were carried out in the original hospitals. Entry criteria were: age 0-18 years, solid malignancy, Lansky score 470%, more than 17 days since the beginning of the last chemotherapy cycle and an ANC 41 Â 10 9 /l with no administration of any hematopoietic growth factor in the previous 8 days. Exclusion criteria were clinical or biological conditions precluding the mobilization or collection procedure. The study protocol was approved by the Comite´pour la Protection des Personnes (CPP Sud Est 6), the Institutional Review Board of Auvergne. Informed written consent was obtained from all the children's parents and, where possible, from the children themselves before their enrollment.
Mobilization and collection regimens
Hematopoietic progenitor cell mobilization consisted of one s.c. injection of 300 mg/kg body weight (BW) of pegfilgrastim (Amgen) without exceeding 12 mg. The choice of the dose was based on data published earlier regarding non-conjugated and pegylated G-CSF. 5 To date, the standard regimen of non-conjugated G-CSF for postchemotherapy mobilization is 5 mg/kg/d. In the steady state, this dose is suboptimal and the standard dose is 10 mg/kg/d. Moreover, a benefit in increasing the dose up to 24 mg/kg/d has been strongly suggested in children. As far as pegfilgrastim is concerned, after chemotherapy the dose of 100 mg/kg has been proposed on the basis of several studies showing that a dose of 100 mg/kg of pegfilgrastim is comparable to a daily administration of 5 mg/kg filgrastim in terms of neutrophil recovery. 12 Hence, in the steady state, there is a rationale for increasing this dose in order to target stem cell mobilization. In healthy volunteers, pharmacokinetic studies have shown that the dose of 300 mg/kg is well tolerated and more efficient than 100 mg/kg for CD34 þ cell mobilization. 5 We therefore assumed that increasing the dose of pegfilgrastim would be safe and more efficient in children with malignancies, as in healthy adults.
Apheresis was started at day 3 after pegfilgrastim administration if a value of 20 CD34 þ /ml cells was present in the blood, or as soon as the level exceeded 10 CD34 þ cells/ml blood after day 3. Apheresis was continued daily for up to four consecutive collections until the required number of cells (set by each patient's own clinician) was achieved. Apheresis was performed using a Cobe Spectra separator (Gambro BCT, Bourg-la-Reine, France) as described elsewhere. 13 The patient's total blood volume was calculated as follows: 80 ml/kg in children aged less than 2 years and 75 ml/kg in older ones.
Evaluation during the study All clinical and biological data were recorded by the same investigator, with particular attention being paid to previously reported adverse events related to filgrastim or pegfilgrastim administration.
14 Evaluation comprised patient history, physical examination, complete blood count with differential reticulocytes and highly fluorescent reticulocytes, complete blood chemistry, lacticodehydrogenase, uricemia and liver functional tests on day 0 and from day 2 to day 11. For the first 13 patients, G-CSF serum concentration was measured (ELISA, Quantikine Human G-CSF Immunoassay Kit, R&D Systems, Inc., Minneapolis, MN, USA). 15 In accordance with French recommendations, abdominal ultrasonography was planned in cases of hyperleukocytosis 470 Â 10 9 /l or clinical splenomegaly. In the case of symptomatic hyperleukocytosis or clinically threatening splenomegaly, an anticipated leukapheresis was planned. The CD34 þ cell count was determined as prescribed by the International Society for Hematotherapy and Graft Engineering guidelines. 16 Functional assessment of HPC was carried out as described earlier. 17 After SCT, neutrophil engraftment was defined as achieved on the first of three consecutive days with a neutrophil count X0.5 Â 10 9 /l after the post transplant nadir. Plt engraftment was defined as occurring on the first of five consecutive days with a plt count X20 Â 10 9 /l without plt transfusions.
Statistical design and analysis
The aim of this trial was to assess the success rate in patients of achieving an optimal HPC harvest defined as at least 5 Â 10 6 CD34 þ cells/kg during the first standard apheresis (less than 3 BVP). The primary motivation for this sequential Bayesian strategy 18, 19 was to provide a formal means of summarizing patient outcome by a single binary event (success or failure). It allowed continuous monitoring of outcomes throughout the trial, and thus was expected to be more efficient in protecting patients from ineffective treatment. 20 We used our experience with mobilization of HPCs in children by using an informative opinion before the beginning of the trial, which was formalized as a prior distribution of the success rate centered on 30%. As the patient outcomes in the trial were recorded, the subsequent distribution of the outcome probability under experimental treatment was computed by applying Bayes' theorem, which yielded a mean estimated success rate with a 95% credibility interval (measure of Bayesian precision). Also, on the basis of this subsequent distribution, early stopping criteria were calculated to allow early termination of the trial: (i) stop for inefficacy if the estimated success rate was unacceptably low compared with the expected rate of 0.3, or (ii) stop for futility if the expected gain from further inclusions in the reliability of the estimated success rate was low (p0.05).
Univariate and multivariate analyses were performed to identify independent predictors of the day on which mobilization kinetics peaked. In the univariate analysis, the variables considered were age, height, body mass index, body area, plt count on day 0, neutrophil blood count on day 0, previous radiotherapy and prior anthracyclin administration. Owing to the small sample size, only the two most significant variables in the univariate analysis were considered in the multiple analysis model.
Statistical analyses were performed using R software (version 2.4, The R Development Core Team). P-values o0.05 were considered significant.
Results
Patient characteristics
Between 1 January 2006 and 1 January 2008, 33 children were consecutively referred to our center for HPC collection. Four declined to enter the study. Three received pegfilgrastim before achieving 1 Â 10 9 /l ANC after chemotherapy and were not included. The characteristics of the 26 patients included are shown in Table 1 .
Mobilization and collection
Sixteen of twenty-six patients met the success criterion. This means that X5 Â 10 6 CD34 þ cells/kg were collected in the first three BVP (representing one standard apheresis). After 26 inclusions, the Bayesian analysis gave a mean estimated success rate of 60.7% (95% credibility interval: 42.0-78.0%). The stopping criterion associated with inefficacy was not met, the probability that the success rate was lower than 30% after 26 inclusions being estimated at 0.0005. The predictive probability of observing two or more successes in the next five patients was 90%. Finally, the stopping criterion based on no significant gain (o0.05) from the next five inclusions, taking into account the width of the credibility interval (the precision), recommended stopping after the inclusion of 26 patients.
Blood and graft compositions are shown in Table 2 . The first apheresis allowed the collection of 8.3 Â 10 6 CD34 þ cells/kg BW (range 0.6-37.8) in a median of 2.8 BVP (range 1.4-3.0). The median value of CD34 þ cells collected in one BVP was 3.0 Â 10 6 CD34 þ cells/kg BW (range 0.4-14.3). Overall, the median number of CD34 þ cells collected/kg was 12.4 Â 10 6 (range 2.7-37.8). The cumulative dose of anthracyclin was the only parameter associated with the total number of CD34 þ cells collected (Po0.05).
Ten patients did not meet the success criterion. A graft of 2.7 Â 10 6 CD34 þ cells/kg was collected in one apheresis in a very low-weight child (6.2 kgs), and the clinician considered a second apheresis unnecessary. Nine patients needed a second (n ¼ 7) or supplementary (n ¼ 2) apheresis to achieve the optimal graft of 5 Â 10 6 CD34 þ cells/kg; six of them achieved this objective. Three heavily pre-treated patients had a final graft of less than 5 Â 10 6 CD34 þ cells/ kg (2.8, 3.7 and 4.3 Â 10 6 CD34 þ cells/kg, respectively, in three, three and four apheresis).
Kinetics of mobilization
The kinetics of mobilization are shown in Figure 1 . In all the patients, the CD34 þ level rose from day 2 (31/ml Abbreviations: BVP ¼ blood volume processed. Collection efficacy (CE) was calculated as follows: CE ¼ total CD34 þ cell count in apheresis product/(pre-apheresis blood CD34 þ cell count Â processed blood volume).
Mobilization with pegfilgrastim in children E Merlin et al blood, range 2-149) to day 3 (80/ml, range 6-353), with a median peak value of circulating CD34 þ cells ranging from 15 to 777/ml, (median 80/ml, mean 135/ml). At day 3, six patients had less than 20 CD34 þ cells/ml blood, whereas at day 4 all patients had at least 10 CD34 þ cells/ml blood. The peak was observed on day 3 in 10/26 patients, and later in 16/26 patients (on day 4 in 13 patients and on day 5 in 3 patients). In univariate analysis, the day of the peak tended to be influenced by age (P ¼ 0.06), height (P ¼ 0.06), body mass index (P ¼ 0.05), body area (P ¼ 0.05) and plt count on day 0 (P ¼ 0.06), but not by absolute neutrophil blood count on day 0 or prior anthracyclin administration. The median total white blood count rose to a maximum level on day 3 (39. /l ¼ 11% of reticulocytes) were observed on day 3. Reduced plt counts occurred in 16/26 patients before the first apheresis (median À9%, max À41% compared with day 0), but they never required transfusion. After mobilization and collection, the start of the following chemotherapy cycle was on day 35 (range 31-42) of the previous cycle. To assess whether the mobilization could affect hematological toxicity of the ensuing chemotherapy round, we looked at the duration of chemo-induced neutropenia after the prior and subsequent rounds for the 12 patients who received similar courses before and after mobilization. Subsequently, there was a 2-day increase in the chemo-induced neutropenia duration (o0.5 Â 10 9 /l) compared with similar earlier cycles (Po0.05).
Safety
Mobilization was clinically well tolerated in 20 patients. No drug-related adverse events of grade X3 occurred. Eleven adverse events of grade p2 occurred in eight patients: mild fever (4), nausea or anorexia (3), myalgias (1) and mild bone pains (1) . Two patients showed asymptomatic splenomegaly (2 cm). No patient had symptomatic hyperleukocytosis; two patients had a peak of leukocytes higher than 100 Â 10 9 /l on day 2 (127 and 110 Â 10 9 /l, respectively) that returned to normal levels by day 10. All patients had increased plasma levels of lacticodehydrogenases, from 1.3 to 3.1 times the normal upper limit. Five patients had asymptomatic hyperuricemia, up to 520 mmol/l (normal: o300 mmol/l).
Pharmacokinetics
The pharmacokinetic study was performed on the first 13 patients (Figure 2 ) and then stopped because of logistical issues. On day 0, G-CSF serum concentrations were undetectable in all but one patient (endogenous secretion). The maximal serum concentrations ranged from 172 to 1410 ng/ml on day 2 (median 724, mean 738). On day 7, G-CSF serum concentrations were undetectable in all patients. Serum G-CSF level on day 2 correlated with the CD34 þ cell peak level (R 2 ¼ 0.535, Po0.005).
Hematopoietic engraftment kinetics after high-dose chemotherapy and SCT At the time of writing this paper, 21 procedures of myeloablative regimen followed by HPC reinfusion had 1 2 3 4 5 6 7 8 9 10 11 0 1 2 3 4 5 6 7 8 9 10 been performed. The number of CD34 þ cells reinfused was 4.5 Â 10 6 CD34 þ cells/kg BW (1.2-12.9). Four patients received a CD34 þ immuno-selected graft. Nine of the twenty-one children received non-conjugated G-CSF from day 1 post-reinfusion to neutrophil recovery. The total ANC recovered by day 11 (median, range 9-22) and plt recovery was achieved by day 15 (median, range 8-49). Long-term data were available for six patients (median follow-up 440 days, range 75-797). The hematological values of these children are shown in Table 3 .
Discussion
Although the optimization of HPC mobilization is particularly desirable in children, little research has been performed in this field. Here, we report the first published data on HPC mobilization by pegfilgrastim in children with malignancies in the hematological steady state. With nonconjugated G-CSF, dose increase and splitting have been suggested to provide better mobilization compared with the standard regimen of non-conjugated G-CSF at 10 mg/kg/d.
2,4
However, in these series, the success criterion of 5 Â 10 6 CD34 þ cells/kg BW was met in o50% of patients, despite the use of large-volume aphereses. This can be compared with our results (60.7% of success, credibility interval 42-78%). Furthermore, with the high dose of pegfilgrastim, all our patients reached the level of 10 CD34 þ cells/ml blood (including heavily pre-treated patients), and none was denied apheresis because of insufficient mobilization. This was not the case in our experience of G-CSF at 2 Â 12 mg/kg/d, wherein 2/32 patients failed to achieve this threshold level. Although this difference is not significant, this could suggest that high-dose pegfilgrastim may be of benefit in heavily pre-treated patients. With pegfilgrastim, the optimal graft of 5 Â 10 6 CD34 þ cells/kg was finally obtained in 22/26 patients. A graft of 10 Â 10 6 CD34 þ cells/kg was collected from 17/26 patients, with 9/26 achieving this level with a single leukapheresis (p3 BVP). Hence, many arguments strongly suggest that one injection of 300 mg/kg pegfilgrastim is at least as efficient as nonconjugated G-CSF for HPC mobilization in the hematological steady state.
This high efficiency is probably due to the fact that the serum G-CSF rises quickly and markedly after the injection, and remains elevated up to the third day. 5 BM stimulation is immediately maximal, as shown by the fact that the ANC does not increase between day 2 and day 3. As a result, the kinetics of pegfilgrastim-induced CD34 þ cell mobilization look slightly different. Although with one daily dose of conventional G-CSF the peak number of peripheral blood CD34 þ cells occurs at day 4 or day 5, 3 the maximum cell concentration after pegfilgrastim administration was reached on day 3 or day 4. As apheresis was started on day 3 for 21 patients, these data do not necessarily reflect the natural mobilization kinetics and have to be considered cautiously. To determine the natural kinetics of mobilization in children with malignancies would imply mobilization without performing an apheresis, and this would be considered unethical. Thus, the kinetics we describe represent the actual clinical situation but not the true natural kinetics of mobilization, as healthy volunteers were used. After the peak level of PBPC is achieved, the cell concentration decreases gradually up to day 5. Hence, in practice, we chose to plan the first apheresis on day 3 if a value of 20 CD34 þ /ml cells were present in the blood, which allowed a second worthwhile leukapheresis on day 4 when the blood level of CD34 þ cell was still high, if necessary. In healthy volunteers and donors, in contrast to postchemotherapy mobilization, 12 pegfilgrastim efficacy is strongly dose-dependent in terms of CD34 þ cell mobilization. 5, 21 In patients with malignancy, the drawback to increasing the dose of pegfilgrastim is that it leads to sustained BM stimulation, which could delay chemotherapy. In adults, high serum concentrations of G-CSF up to 12 days after a pegfilgrastim injection have been reported in the context of the reduction of chemotherapy-induced neutropenia. 22 Consequently, there is a significant risk that cycling cells may be exposed to chemotherapy, resulting in secondary neutropenia. The situation is quite different in the context of the hematological steady state. As pegfilgrastim is essentially metabolized by polynuclear cells, a high ANC provides a faster decrease in this exposure. 5 In our patients, G-CSF serum concentrations declined dramatically after the third day following injection, and were undetectable by day 7. It is of note that we found a slight increase in chemo-induced neutropenia duration after mobilization. As the benefit of avoiding a few s.c. injections could be questioned if this led to prolonged neutropenia, it is important to determine whether this increase exists with high doses of unconjugated G-CSF. Table 3 Long-term hematological follow-up after myeloablative regimen and stem cell reinfusion Owing to the small size of the pediatric population, and as the outcome is achieved soon after inclusion, the sequential Bayesian approach offered the best means of conducting this phase IIA trial in a reasonable time. We determined the prior distribution of the success rate, centered on 30%, based on our experience and on two historical cohorts of children who received non-conjugated G-CSF at 10 mg/kg/d or at 2 Â 12 mg/kg/d for mobilization. In these cohorts, the success rates were 48/120 (40%, 95% CI 31-49%) and 17/32 (53%, 95% CI 36-70%), respectively. If another threshold had been chosen, the trial would not have been interrupted, and the retrospective response means for prior means of 40 and 50% would have been 60.8% (42.1-78%) and 61.1% (42.1-78.2%), respectively. If 10 additional patients had been included in the trial, the probability of observing more than four responses would have been 81%, and the probability of observing more than five responses would have been 63.6%. Using these predictive probabilities to calculate a stopping rule for futility of further inclusions allowed us to recommend trial cessation after 26 patients. However, we acknowledge that it is a small sample and that larger comparative studies are needed.
Moreover, the small size of our study requires that the short-and long-term safety of receiving such a high dose of hematopoietic growth factor be confirmed. If any adverse event arises after pegfilgrastim injection, it is impossible to stop the mobilization process, in particular, in cases of hyperleukocytosis. We would like to point out that in our series two patients had 4100 Â 10 9 /l leukocytes. Although none of them showed clinical symptoms, this could be a concern and larger studies in the future should address this possible serious side effect. In our experience of children who received G-CSF at 10 or 20 mg/kg/d, no such increase was reported. 23 However, these levels were observed with G-CSF administered at 2 Â 12 mg/kg/d. 4 Splenic rupture has been reported in adults as a potential adverse event following pegfilgrastim injection, 24 but some similar events were reported earlier with non-conjugated G-CSF. 25 The long-term risk of myelodysplasia or selection of a clone has been shown after intensive chemotherapy in ALL, G-CSF being an independent risk factor. 26 In the context of solid tumors, the role of G-CSF remains unclear. In mobilization, this theoretical risk could be amplified by the increased dosage of G-CSF, but this remains hypothetical.
Given these results, we have adopted this scheme of HPC mobilization in a situation in which a large quantity of cells is required, or in heavily pretreated patients, and provided that the next treatment can be slightly delayed. One approach to reducing this delay could consist of injecting a reduced dose of pegfilgrastim earlier after prior chemotherapy, and adjusting the dose on the ANC. Also, the simplicity of using pegfilgrastim allows the individualization of treatment, with the possibility of a nonconjugated G-CSF boost if necessary.
In conclusion, this study shows that a single injection of 300 mg/kg pegfilgrastim in the hematological steady state is an efficient, well-tolerated method of HPC mobilization in children. Given the small and heterogeneous patient cohort and the lack of an appropriate control, we cannot state that pegfilgrastim is more efficient than unconjugated G-CSF.
However, the combination of predictable mobilization kinetics, a good acceptance profile and an efficacy that appears at least as good as with unconjugated G-CSF, offer several interests for the HPC mobilization process in children. This justifies large randomized clinical trials to investigate whether the use of pegfilgrastim will translate into clinical benefit for children with cancer. Our data may aid the design of such studies.
